Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral pyridostigmine for acute colonic pseudo-obstruction
ACTRN12621000254897Phase 2Not yet recruiting
- Sponsor
- Eastern Health
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pyridostigmine in Ogilvie syndrome (ACPO) (2 arms), sponsored by Eastern Health. Primary endpoint: Passage of bowel motions. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
pyridostigmine
03
Conditions
Ogilvie syndrome (ACPO)
Beyond the preview
Go deeper on ACTRN12621000254897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000254897.